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Abstract
Background: Prognostic biomarkers are needed for superficial gastroesophageal adenocarcinoma (EAC) to predict clinical
outcomes and select therapy. Although recurrent mutations have been characterized in EAC, little is known about their
clinical and prognostic significance. Aneuploidy is predictive of clinical outcome in many malignancies but has not been
evaluated in superficial EAC.
Methods:We quantified copy number changes in 41 superficial EAC using Affymetrix SNP 6.0 arrays. We identified recurrent
chromosomal gains and losses and calculated the total copy number abnormality (CNA) count for each tumor as a measure
of aneuploidy. We correlated CNA count with overall survival and time to first recurrence in univariate and multivariate
analyses.
Results: Recurrent segmental gains and losses involved multiple genes, including: HER2, EGFR, MET, CDK6, KRAS (recurrent
gains); and FHIT, WWOX, CDKN2A/B, SMAD4, RUNX1 (recurrent losses). There was a 40-fold variation in CNA count across all
cases. Tumors with the lowest and highest quartile CNA count had significantly better overall survival (p = 0.032) and time to
first recurrence (p = 0.010) compared to those with intermediate CNA counts. These associations persisted when controlling
for other prognostic variables.
Significance: SNP arrays facilitate the assessment of recurrent chromosomal gain and loss and allow high resolution,
quantitative assessment of segmental aneuploidy (total CNA count). The non-monotonic association of segmental
aneuploidy with survival has been described in other tumors. The degree of aneuploidy is a promising prognostic biomarker
in a potentially curable form of EAC.
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Introduction
The last several decades have witnessed a substantial increase in
the incidence of gastroesophageal adenocarcinoma (EAC) in the
United States [1,2]. The outcome and treatment strategy for EAC
depends on the extent of local invasion and presence of regional or
distant metastases at the time of diagnosis [3,4]. Superficially
invasive (EAC), because of the lower predicted risk of metastases
relative to more locally advanced EAC, is potentially cured by
esophagectomy or endoscopic resection [5,6]. However, a subset
of patients with superficial EAC develops regional and distant
metastases and succumbs to their disease [7,8]. Because of the
broad range of potential treatment modalities [9] and clinical
outcomes, superficial EAC requires accurate prognostication at
the time of initial diagnosis when clinically aggressive tumors have
the greatest chance of cure. Prognostic biomarkers are conse-
quently more likely to impact the care of patients with superficial
EAC.
Genomic instability contributes to malignant transformation by
generating the clonal diversity that allows for the development of
increased growth rates, invasion and metastasis in cancer cells [10–
12]. Genomic instability and resultant aneuploidy is an early event
in the pathogenesis of EAC. When detected in Barrett’s esophagus
it is a risk factor for progression to EAC [13]. Relative to other
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tumor types, EAC is known to exhibit a higher degree of
chromosomal aneuploidy, characterized by loss and gain of whole
chromosomes and shorter chromosome segments [14]. This
deregulates genes in EAC by several mechanisms, including
segmental amplification of oncogenes (e.g. EGFR, HER2, MET,
KRAS, MYC); focal inactivating deletion of tumor suppressor
genes (e.g. CDKN2A, FHIT); and point mutation of tumor
suppressor genes (e.g. TP53) and accompanying copy neutral loss
of heterozygosity [15–19]. Although previous reports have
characterized genes involved in the pathogenesis of EAC by high
throughput sequencing and array-based methodologies, none has
focused on genomic instability in EAC and its potential prognostic
significance. Moreover, none of these previous studies has
specifically addressed the potentially curable subset of EAC that
are limited to the superficial layers of the esophagus that may
represent an early form of EAC.
Aneuploidy, when assessed by crude measurement of DNA
content, is associated with worse prognosis in colon and lung
cancer [20,21], but there is conflicting data for EAC [22–24].
High density SNP array or array CGH can quantitatively assess
segmental aneuploidy at high resolution. Recent studies have
found that the total copy number abnormality (CNA) burden
correlates with other measures of chromosomal instability in breast
cancer cell lines [25] and is associated with poor prognosis in
chronic lymphocytic leukemia and melanoma [26,27]. However,
the association between genomic instability and tumor behavior is
complex. Experimental induction of severe chromosomal instabil-
ity in cell lines can cause tumor cell death [28]. Furthermore, there
is evidence in multiple solid tumors of a favorable prognosis
associated with extreme levels of chromosomal instability [29–31].
To address the association of genomic instability with the
clinical behavior of superficial EAC, we evaluated 41 tumors on
the high density Affymetrix SNP 6.0 array to identify regions of
CNA. This allowed us to quantify CNAs across the entire genome
and assess the prognostic significance of segmental aneuploidy in
each tumor. We also assessed the prevalence of gains and losses
involving genes with a known pathogenic role in EAC to establish
their prevalence in this potentially curable subset of EAC and
identified several novel chromosomal regions harboring genes not
hitherto implicated in the pathogenesis of EAC.
Methods
Clinical pathologic and survival variable definitions
This study was approved by the University of Pittsburgh
Institutional Review Board with waiver of consent because the
research involved the use of excess tissue obtained for routine
treatment purposes and posed no more than minimal risk to
subjects. The data were analyzed anonymously. The clinical and
pathologic records were searched to identify superficial esophageal
and gastroesophageal junction adenocarcinomas that were treated
by esophagectomy between 1996 and 2010 without induction
therapy. Barrett’s esophagus was defined as esophageal intestinal
metaplasia confirmed histologically in either pre-operative biopsy
or in the esophagectomy specimen. Tumors location was classified
as gastroesophageal junction (GEJ) or esophageal based on the 7th
edition AJCC criteria. Tumor specific pathologic variables were
confirmed on pathologic review. Patient age and sex were
obtained from the clinical record. Time to first recurrence was
defined as the time from esophagectomy to first documented
recurrence (locoregional or distant) and censored at the last clinical
evaluation for recurrence. For overall survival, death was
determined from review of the patient’s clinical history as well as
the social security death index and survival was censored at the
time of last contact. Details of post-operative chemotherapy and/
or radiation therapy were available in the medical record at our
institution for 23 of 41 patients because many patients receive
adjuvant therapy (when needed) at other institutions.
Statistical analysis
Differences in categorical variables were assessed by chi-squared
test or Fisher’s exact test when appropriate. Differences in
continuous variables were evaluated by Mann-Whitney U Test.
Pearson’s coefficient r or Spearman’s rho was calculated to
evaluate the correlation between continuous variables. Survival
differences between groups were evaluated by comparing Kaplan-
Meier survival functions with log rank test and Cox proportional
hazards analysis. Significant differences were defined by p-value,
0.05. All statistical tests were two sided. Calculations were
performed using SPSS version 20 (IBM Corporation, Armonk,
NY).
Tissue selection
Superficial EAC were screened to identify tumors with
adequately preserved, formalin fixed paraffin embedded (FFPE)
tissue suitable for DNA extraction. Tumors exhibiting extensive
autolysis were excluded. Tumors greater than 1 cm with high
tumor epithelial cellularity were chosen for DNA extraction.
Histologically benign lymph nodes between 0.5 and 1.0 cm were
chosen as matched normal control tissue for each tumor due to the
high DNA content of this tissue. They were histologically
confirmed as benign on a minimum of three recut sections from
the paraffin block. Ten 10 micron sections of tumor were
macrodissected from glass slides guided by a serial H&E section
to minimize admixture of normal tissue and ensure .75% tumor
DNA content. Matched normal lymph node tissue was processed
similarly from ten 10 micron sections.
DNA isolation, hybridization and array processing
Genomic DNA from the FFPE tumor and matched FFPE
normal samples was prepared for hybridization to the array using
modifications of the procedures described by Thompson et al. and
Teufferd et al. [32,33] Genomic DNA was purified from formalin-
fixed, paraffin embedded (FFPE) tumor and normal lymph node
tissue according to a modified protocol for the QiaAmp DNA
FFPE Tissue Kit (Qiagen, Valencia, CA). For each macrodissected
specimen, tissue was placed into 2.0 ml Eppendorf tubes for
deparaffinization through successive xylene and ethanol washes.
Deparaffinized tissue was resuspended in Qiagen ATL buffer plus
Proteinase K (300 ul) (.600 mAU/ml) followed by incubation
(18 hours at 56uC) with shaking at 600 rpm in a thermomixer heat
block (Eppendorph, Hauppauge, NY). Following tissue lysis and
protein removal, samples were placed at 90uC for 1 hour to
remove formalin crosslinking. Genomic DNA eluted from the
QIAamp column was suspended in 53 ml of Buffer AE (Qiagen)
and subjected to spectrophotometric analysis (NanoDrop, Wil-
mington, DE). Samples with absorption ratio of 260/280.1.8
were evaluated for DNA integrity using an Agilent Bioanalyzer
12000 DNA chip (50 ng/ul). Only samples with fragment sizes in
the 1000 bp–3000 bp range (FU$5) were included in subsequent
microarray assays. Single nucleotide polymorphism analysis was
performed using a modified version of the Affymetrix Genome-
Wide SNP 6.0 protocol (Affymetrix, Sunnyvale, CA). Individual
one microgram Sty I and Nsp I restriction digests (New England
Biolabs, Ipswich, MA) were carried out and ligated with the
matching adaptor (Sty or Nsp) provided in the Affymetrix 6.0
protocol. Twelve PCR reactions per sample were performed (6-Sty
I digest/ligation reactions, 6-Nsp I digest/ligation reactions)
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followed by purification of PCR products using standard
isopropanol precipitation (RT) followed by 70% ethanol precip-
itation on ice. DNAse 1 fragmentation was performed on 220 ug
of pooled PCR product (110 ug STY and 110 ug NSP) and the
fragmented DNA was biotinylated and end-labeled. Samples were
then hybridized on Genome-Wide SNP 6.0 arrays for 18 hours at
50uC with rotation (60 rpm) in an Affymetrix Gene Chip
Hybridization Oven (Model 640). The arrays were washed,
stained and scanned according to the Affymetrix Genome-Wide
SNP 6.0 protocol using the Affymetrix GeneChip Fluidics Station
(Model 450), GeneChip Scanner 3000 7G, and GeneChip
Command Console (v3.0) software.
Affymetrix Genotyping Console software (Affymetrix, Sunny-
vale, CA ) was used to assess array data quality metrics (QC call
rate and contrast QC). Affymetrix CEL and CHP files were
transferred to Partek Genomics Suite (Partek Inc., St Louis, MO)
for copy number analysis. Copy number was generated by
comparing the hybridized intensities of each tumor array with the
matched normal DNA sample from the same patient. Copy
number measurements were smoothed based on local guanine-
cytosine content using a 1-megabase window. The Partek
segmentation algorithm was used to identify regions of significant
variation from normal, consisting of a minimum of 20 genomic
markers and p-value,0.0005, with signal to noise set at 0.7 and
expected range 1.7 to 2.3 under the assumption that each tumor
was diploid. Segmentation results are detailed for each case in
Table S1. Human genome assembly hg19 was used to annotate
each segment. All CEL and CHP files used for the study are
accessible through the NCBI Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/, accession number GSE49396).
Analysis of segmental aneuploidy by total CNA count
After segmentation of individual cases, a database of all genomic
segments harboring copy number abnormalities was used to
calculate the number and size of all independent copy number
abnormalities (CNAs) found in each individual tumor. An
independent CNA was defined as a segment with copy number
outside the pre-defined range of 1.7–2.3 that was not contiguous
with an adjacent independent CNA of identical copy number.
This measure is nearly identical to the total breakpoint count
method previously described [25]. By this definition, adjacent
segments with unequal copy number were defined as independent
CNAs. We quantified the degree of segmental aneuploidy in each
tumor by the total number of independent CNAs.
Identifying candidate target genes in regions of recurrent
CNA
We recognized candidate genes by identifying chromosome
segments with extreme CNA (outside the range 1.474–3.025) in at
least 3 of 41 cases. The boundaries of this range represent the 10th
and 90th percentile copy number for all segments that fell outside
the normal range. The lateral boundaries of target chromosomal
regions were conservatively defined as regions with extreme CNA
in at least 2 cases (provided the segment spanned a region of
extreme CNA in at least 3 cases). Each target segment was
mapped back onto the human genome (assembly hg19) manually
using the University of California at Santa Cruz Genome Browser
(http://genome.ucsc.edu) [34] in order to identify the candidate
genes spanned by targeted segments. The frequency of gain or loss
of candidate driver genes was determined by the frequency of
extreme CNA involving any portion of the chromosome spanned
by the consensus coding sequence of the candidate gene.
FISH validation of copy number abnormalities for MYC
and EGFR
Tumor samples (0.6 mm cores) from all 41 cases were arrayed
in duplicate or triplicate on tissue microarrays as previously
described [35], sectioned and co-hybridized with gene- and
centromere-specific probes as previously described [36], We co-
hybridized a 120 kbp SpectrumOrange-labeled DNA probe
targeting the MYC region of chromosome 8q24 (Abbott
Molecular, Des Plaines, IL) along with a SpectrumGreen-labeled
chromosome 8 centromeric probe (CEP8, Abbott Molecular, Des
Plaines, IL). We also co-hybridized a SpectrumOrange-labeled
303 kbp DNA probe targeting the EGFR region of chromosome
7p12 (Abbott Molecular, Des Plaines, IL) along with a chromo-
some 7 centromeric probe (CEP7, Abbott Molecular, Des Plaines,
IL). The number of gene specific probe signals and centromere
signals per tumor nucleus were counted in a minimum of 30 tumor
cell nuclei to compute the average EGFR/CEP7, EGFR/nucleus,
MYC/CEP8 and MYC/nucleus ratios. Amplification was pre-
defined as EGFR/CEP7.2.0 or MYC/CEP8.2.0, following the
guidelines for clinical detection of HER2 amplification in
adenocarcinoma of the stomach and GE junction [37].
Results
Clinical and pathologic characteristics of the study
population
Clinical and pathologic features of the study cohort are
summarized in Table 1 and detailed for each case in Table 1.
All 41 tumors were treated by esophagectomy without induction
therapy in a single institution. The majority were male and over
age 66. Forty percent of tumors were located in the esophagus with
the remainder classified as GE junction adenocarcinomas. The
large majority (85%) were encountered in a background of
intestinal metaplasia (Barrett’s esophagus) either in the pathologic
specimen itself or in pre-operative biopsy. All but one tumor was
staged T1, including 6 T1a (confined to the mucosa) and 34 T1b
(invasion into the submucosa). One tumor was re-staged from T1
to T2 on pathologic review of recut levels of the tumor. Almost
40% of tumors were metastatic to one or more regional lymph
nodes and one patient had a distant metastasis (stage M1) at the
time of esophagectomy.
Target identification heuristic identifies known and novel
genomic targets of copy number gain and loss in EAC
All segments with at least one CNA falling outside the 1.7–2.3
range are listed in Table S2. We filtered this list to identify
chromosomal segments targeted in at least three superficial EAC
by extreme CNA falling outside the range of 1.474–3.025 (see
Methods). Regions of CNA are more likely to be biologically
significant when they show extreme copy number change and are
identified in multiple tumors [38]. The genomic regions identified
by our heuristic approach are listed in Table S3 and Table S4.
Our results are validated by the fact that a large number of the
targets of gain and loss have been previously reported in at least
one of three large studies of chromosomal copy number changes in
gastric and esophageal adenocarcinoma that examined over 100
tumors using hybridization array platforms [14,16,19].
We also report several novel targeted gains involving ERBB4,
PDGFRA, CDH6 and PTPN11 (Table S3) and focal regions of
copy loss overlapping MAML2, JAK2 and ERG (Table S4). Our
heuristic approach identified recurrent, megabase size deletion
regions spanning multiple genes on chromosomes 11q24-q25,
21q22.3 and 22q11.1-q11.21. These larger regions span multiple
Aneuploidy in Esophageal Adenocarcinoma
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genes of potential biological relevance such as CHEK1 and ETS1
(11q24-q25), SUMO3 (21q22.3) and BID (22q11.1-q11.21) (Table
S4). These putative targets require further validation and
evaluation to establish their biological significance in EAC and
exclude the possibility of false discovery inherent in the analysis of
large datasets.
Recurrent CNAs in superficial EAC frequently target
genes known to be associated with gastroesophageal
carcinogenesis
Although the heuristic criteria we employed detected a majority
of previously characterized significant gains or losses in EAC, we
specifically interrogated our data to determine the frequency of
extreme CNA occurring in a list of candidate genes specified in
two recent, large studies of gastric and esophageal adenocarcino-
ma using high density SNP arrays in order to detect rare events
(involving ,3 cases) in these significant regions (Table 2) [14,19].
We found evidence of gains in 13 of 19 (68.4%) amplified genes
and loss in 11/15 (73.3%) genes targeted by deletion that were
reported by Deng et al. and Dulak et al. (Table 2).
In our cases, copy gain in HER2, EGFR and MET receptor
tyrosine kinases (Table 2) were generally mutually exclusive.
However, in one case we detected co-amplification of HER2 and
EGFR and in one other case there was co-amplification of HER2
and MET. KRAS gains also occurred in one case with HER2 gain
and in one case with MET gain. No case had evidence of copy
gain in more than two of these genes. Interestingly, we also found
evidence of focal KRAS loss in 3 (7.3%) cases. This was not
observed in conjunction with gains of HER2, EGFR or MET.
Overall, 18/41 (43.9%) cases had copy gain of at least one kinase
(HER2, EGFR, MET and KRAS) capable of activating down-
stream MAP kinase signal transduction.
GATA4 and GATA6 are zinc finger transcription factors.
GATA4 regulates gastric epithelial differentiation [39] and
interacts with CDX2 to regulate intestinal gene expression [40]
among other roles during embryogenesis. GATA6 plays a
significant role in human pancreatic organogenesis [41], and is
amplified and overexpressed in pancreatic cancer [42]. There is
evidence that it functions as a lineage survival oncogene in
esophageal adenocarcinoma [43]. RUNX1 is a transcription
factor with frequent inactivating mutations in myeloid leukemia
[44].
Cell cycle deregulation appears to be a dominant theme in the
pattern of recurrent CNAs in superficial EAC, including recurrent
amplification of CCND1, CCNE1 and CDK6 and frequent
deletion of CDKN2A. Inactivation of genes known to play a role
in sensing and responding to DNA damage is another recurrent
theme in superficial EAC. Deletion of FHIT was the most
common CNA detected (involving 23/41 cases). Loss of FHIT, a
tumor suppressor that functions as a sensor of genotoxic stress,
may confer resistance to and permit accumulation of DNA
damage [45]. WWOX was the second most common deletion
event (involving 10/41 cases). WWOX encodes a protein that
interacts with p73 and p53 and regulates cellular response to
genomic damage; expression is lost in many malignancies in
addition to gastric and esophageal adenocarcinoma and it
functions as a tumor suppressor [46]. FHIT, WWOX span fragile
sites (FRA3B and FRA16D) that are frequently mutated in
precursor lesions to EAC, including Barrett’s esophagus and
Barrett’s associated dysplasia [15,17,47].
Although mutations in TP53 are among the most common
mutations in esophageal adenocarcinoma based on whole exome
sequencing [18], copy number abnormalities involving TP53 were
not observed in our cases, a fact that has been previously noted in
other reports [17].
FISH validation of CNAs involving EGFR and MYC
In order to confirm the SNP array assessment of copy number
change in the tumors, we performed FISH using probes targeting
EGFR and MYC with corresponding centromeric probes (CEP7
and CEP8, respectively). FISH for EGFR was successfully
performed on 39 of 41 cases (Figure 1). There was a significant
correlation between copy number by SNP array and EGFR/
CEP7 as well as EGFR/nucleus ratios by FISH (Pearson’s
r = 0.926 and 0.861 respectively, p-value,0.001 for both). All
three cases with high level amplification (EGFR/CEP7.15) by
FISH showed copy gain by SNP array. There were two cases with
low level amplification by FISH (EGFR/CEP7= 2.0–4.0) that
were not detected by SNP array (copy number within the normal
range of 1.7–2.3). Of the six cases detected by SNP array (copy
number.3.025), one case was unsuccessful by FISH, three were
amplified at a high level, one case was borderline (EGFR/
CEP7= 1.89) with an average of over six copies of EGFR per
nucleus. The last case was not amplified by FISH (EGFR/
CEP7= 1.13), possibly due to tumor heterogeneity given that the
average copy number in the EGFR region by SNP array was 11.0.
All 41 cases were successfully evaluated for MYC amplification
by FISH (Figure 1). There was a significant correlation between
copy number by SNP array and both MYC/CEP8 and MYC/
nucleus ratios by FISH (Pearson’s r = 0.712 and 0.643, respec-
tively; p-value,0.001 for each). Four of the five cases that were
amplified by FISH also showed copy gain by SNP array (copy
number.3.025). One FISH amplified case had lower level copy
number gain (copy number= 2.7) in the MYC region by SNP
Table 1. Clinical and Pathologic Characteristics of the Study
Population.
Clinical and Pathologic Characteristics All Patients
N (%)
Sex Female 6 (14.6)
Male 35 (85.3)
Age, median (IQR) 66 (60–74)
Mass Location Esophagus 16 (39.0)
GE Junction 25 (61.0)
T Stage T1a 6 (14.6)
T1b 34 (82.9)
T2 1 (2.4)
N Stage N0 26 (63.4)
N1 10 (24.3)
N2 or N3 5 (12.1)
No. LN resected, median (IQR) 23 (14–27)
M Stage M0 40 (97.6)
M1 1 (2.4)
Tumor size (cm), median (IQR) 2.5 (1.8–4.0)
Tumor grade WD or MD 25 (61.0)
PD 16 (39.0)
Barrett’s Esophagus No 6 (14.6)
Yes 35 (85.4)
doi:10.1371/journal.pone.0079079.t001
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array. Conversely, all four cases with copy gain by SNP array (.
3.025) were amplified by FISH.
Relative frequency and size of CNAs varies considerably
in superficial EAC
EAC is known to exhibit greater aneuploidy than gastric (not
including GE junction) and colonic adenocarcinoma as reflected in
a greater number of arm-level and focal gains and losses [14]. We
quantified the degree of aneuploidy in each tumor by evaluating
the cumulative number of independent CNAs (copy number
falling outside the normal range of 1.7–2.3). CNAs were not
distributed evenly throughout the genome. They were most
frequent in chromosomes 3 and 7 and least frequent in
chromosomes 10, 14 and 19. Amplifications outnumbered
deletions by a factor of 1.7.
The frequency of CNAs ranged from 11 to 433 per tumor
(Figure 2) with a median of 82 (IQR, 46–139), indicating a wide
variation in genomic complexity in superficial gastroesophageal
adenocarcinoma. Individual chromosomes also showed consider-
able variation among different tumors (Figure 2 and Figure 3). As
expected, there was a strong correlation between total CNA count
and total CNA count for gains or losses alone (Figure 2). The heat
map (Figure 2) illustrates that tumors with high total CNA counts
tend to have elevated CNA counts throughout the genome,
Table 2. Prevalence of Copy Gains and Losses in Superficial EAC in Previously Reported Candidate Genes.
Cytoband Previously Reported Candidate Gene(s) Reference(s)
Present Study Frequency of
CNA, N (%)
Gains
12p21.1 KRAS 13,18 4 (9.8)
18q11.2 GATA6 13,18 4 (9.8)
8p23.1 GATA4 13,18 4 (9.8)
19q12 CCNE1 13,18 2 (4.9)
7q21.2 CDK6 13,18 4 (9.8)
11q13.2 CCND1, FGF3, FGF4, FGF19 13,18 8 (19.5)
17q12 HER2 13,18 8 (19.5)
7p11.2 EGFR 13,18 6 (14.6)
8q24.21 MYC 13,18 4 (9.8)
6p21.1 VEGFA 13 4 (9.8)
7q31.2 MET 13,18 4 (9.8)
12q15 MDM2 13 0 (0)
7q34 EPHB6 13 0 (0)
6q23.3 MYB 13 0 (0)
1q21.3 MCL1 13 0 (0)
10q26.12 FGFR2 13,18 0 (0)
3q26.2 PRKCi 13 0 (0)
5p14.3 near CDH12 18 1 (2.4)
13q22.1 KLF5 18 3 (7.3)
Losses
3p14.2 FHIT 13,18 23 (56.1)
16q23.1 WWOX 13,18 10 (24.2)
9p21.3 CDKN2A/B 13,18 6 (14.6)
5q11.2 PDE4D 13,18 1 (2.4)
20p12.1 MACROD2 13 6 (14.6)
4q22.1 FAM190A 13 1 (2.4)*
18q21.2 SMAD4 13 6 (14.6)
21q22.12 RUNX1 13 6 (14.6)
9p24.1 PTPRD 13,18 4 (9.8)
6q26 PARK2 13 0 (0)
4q35 CASP3 13 0 (0)
11q22.3 ATM 13 0 (0)
6p25.3 GMDS 18 3 (7.3)
13q14.2 RB1 18 0 (0)
8p23.1 CSMD1 18 1 (2.4)
*large deletion region.
doi:10.1371/journal.pone.0079079.t002
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evidenced by CNA counts above the median in the majority of
their chromosomes. However, the correlation between total CNA
count (including all chromosomes) and individual chromosomal
CNA counts was better for chromosomes with relatively high CNA
counts than those with low CNA counts (Figure 2).
Among the 4394 CNAs identified in the entire data set, the size
of CNAs varied from sub-kilobase focal events to 155 Mb arm-
level events. When grouped by size, 1.6% were ,1 kb; 20.2%
were 1–10 kb; 35.1% were 10–100 kb; 17.9% were 100 kb-1 Mb;
17.9% were 1–10 Mb; and 7.2% were .10 Mb. The median size
of CNAs as we have defined them was 41.3 kb (IQR, 11.9 kb–
1.04 Mb). The size of CNAs varied from tumor to tumor with the
median size in a given tumor ranging from 7.4 kb to 266 kb. Four
cases lacked any CNAs greater than 10 Mb; two of these had
CNAs distributed throughout all smaller size ranges up to 10 Mb
and the other two cases had .90% of CNAs less than 100 kb.
Total CNA count is not associated with chromosome 7 or
8 copy number by FISH; FHIT deletion or WWOX deletion
We also evaluated whether total CNA count was associated with
chromosome 8 or chromosome 7 copy number (based on
centromeric FISH) as an independent, but indirect assessment of
tumor ploidy. Polyploidy could reduce the detection of single copy
gains and losses by SNP array [48] and possibly explain low CNA
counts. We separated tumors into three groups: high CNA count
(highest quartile), low CNA count (lowest quartile), intermediate
CNA count (cases in the middle 2 quartiles). There was no
difference among CNA count groups in the average chromosome
8 copy number by FISH (2.0, 2.2 and 2.1 in the low, intermediate
and high CNA groups, respectively; p= 0.368, Kruskal-Wallis
ANOVA), nor in the in the average chromosome 7 copy number
by FISH (2.3, 2.7 and 2.9 in the low, intermediate and high CNA
groups, respectively; p= 0.345, Kruskal-Wallis ANOVA). Lastly,
there was no significant correlation between chromosome 7 or 8
CNA count and chromosome 7 or 8 ploidy by FISH (data not
shown). These data suggest that tumor ploidy does not significantly
alter the total CNA count.
FHIT and WWOX genes play a role in regulating response to
DNA damage and mutations in these two genes might be more
common in tumors with elevated CNA counts. We found that
40% of tumors in the low CNA count group had FHIT deletion,
compared to 62% and 60% of intermediate and high CNA count
cases, respectively (p = 0.600, Fisher’s exact test). Likewise, we
found that 10% of low CNA count tumors had WWOX deletion
compared to 29% and 30% of intermediate and high CNA count
tumors, respectively (p = 0.629, Fisher’s exact test). Similarly, the
Figure 1. Representative EGFR and MYC FISH Results. FISH to determine EGFR and MYC copy number. Gene specific probes are labeled red
(EGFR and MYC) while corresponding centromere probes (CEP7 and CEP8, respectively) are labeled green. (A) Tumor cells with a near normal 1:1 ratio
of EGFR/CEP7 and approximately 2 signals from each probe per cell. (B) High level EGFR amplification. EGFR amplification was detected as clusters of
numerous red fluorescent signals which is a characteristic pattern caused by high EGFR copy number (see reference [57]) with variable chromosome 7
centromere copy number. (C) Tumor cells with a near normal MYC and centromere 8 copy number. (D) High level MYC amplification characterized by
numerous MYC signals per cell and a high MYC/CEP8 ratio.
doi:10.1371/journal.pone.0079079.g001
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mean CNA count among cases with FHIT mutation or WWOX
mutation was not significantly different from cases lacking these
mutations (data not shown, Mann-Whitney U Test p.0.05 for
both).
Total CNA count does not correlate with data quality
metrics
Formalin fixation, which increases hybridization noise and
reduces SNP array data quality relative to high quality frozen
tissues [32,33], could influence relative CNA counts. There was no
correlation between total CNA count and standard array data
quality metrics (QC call rate and contrast QC), indicating that the
differences in CNA count were not an artifact caused by technical
noise (Table S5).
Total CNA count is associated with prognosis in
superficial EAC
In the population of 41 cases, there were 19 deaths and 11
documented recurrences with a median follow up interval of 46
months (range 2.2–104 months). Two patients died within 3
months of surgery of post-surgical complications and were
excluded from the analysis of overall survival. Recurrences were
diagnosed at 16.5 months post-surgery on average (range 7–27
months). All 11 patients with tumor recurrence died.
We evaluated the prognostic significance of total CNA count in
the three groups (low, intermediate and high) based on CNA
count. The Kaplan-Meier survival curves reveal that patients with
tumors characterized by intermediate CNA count had significantly
worse overall survival outcomes than those falling into the highest
or lowest quartiles (p-value = 0.032, Figure 4A). This same pattern
was observed in time to first recurrence which is a better indicator
of aggressive tumor behavior in superficial cancers (p-val-
ue = 0.010, Figure 4B).
The CNA count groups had no significant differences with
respect to known pathologic prognostic variables (TNM stage,
Figure 2. Heatmap Depicting the Correlation between Total
CNA Count in Each Tumor and Total Copy Number Gains, Total
Copy Number Losses and Total CNA Count by Chromosome.
Cases are ordered from lowest to highest total CNA count down the
left-most column. Lowest counts in each column are blue and the
highest counts in each column are red as illustrated in the color scale
below. In adjacent columns, the heatmap shows the correlation of total
CNA count with total copy number gains, total copy number loss and
total CNA count by chromosome. The heatmap illustrates that as total
CNA count increases, the frequency of gains and losses increase and the
frequency of CNA counts tends to increase throughout all chromo-
somes. Correlation coefficients for each column with total CNA count
(Pearson’s r) are listed below with the corresponding p-values.
doi:10.1371/journal.pone.0079079.g002
Figure 3. Schematic Illustration of Copy Number Abnormalities in Two Tumors Representing High and Low CNA Count and a
Spectrum of Genomic Complexity. For both A and B, the horizontal axis represents position of segments along chromosome 7 (in Mb) and the
vertical axis represents estimated copy number (truncated at 16). (A) Tumor 2515 (dark grey) has a large number of independent CNAs on
chromosome 7 (N= 56), including a complex copy number gains at ,55 Mb (region of EGFR) as well as other gains and losses throughout the
chromosome. (B) By contrast, tumor 2634 (light grey) has few independent copy number changes (N= 2, gain at ,39 Mb and loss at ,97.4 Mb). For
this illustration, copy numbers in the normal range of 1.7–2.3 were assigned a value of 2.
doi:10.1371/journal.pone.0079079.g003
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angiolymphatic invasion, tumor size, tumor grade, number of
lymph nodes resected, Table 3). Multivariate analysis was
performed to adjust for confounding prognostic variables. On
univariate analysis, intermediate total CNV count was an adverse
prognostic factor (HR 3.7, 95% CI 1.3–10.7) and remained a 3.4-
fold increased hazard of death (95% CI 1.1–10.4) after adjusting
for other borderline or significant (p-value,0.2) predictors of
survival (N stage, angiolymphatic invasion and tumor size).
Similarly, it was associated with a 7.3-fold increased risk of
recurrence and remained a significant predictor of time to first
recurrence (HR 7.3, 95% CI 1.5–34) after adjusting for
angiolymphatic invasion (the only other variable with a borderline
association with recurrence, p-value,0.2). Factors evaluated in the
multivariate analyses included patient age, N stage, angio-
invasion, tumor size, tumor grade and number of lymph nodes
resected. We had data on adjuvant therapy for only 23 of 41 cases.
In these 23 patients, administration of post-operative chemother-
apy and/or radiation therapy was not a significant prognostic
factor (HR 1.423, 95% CI 0.3–5.9) with respect to overall survival.
The lack of complete data precluded inclusion of this variable in
the multivariate analysis.
Discussion
Although the spectrum of sequence-level and chromosome-level
mutations that contribute to the pathogenesis of EAC are
increasingly well characterized [14–18], no previous study has
explored the clinical significance of chromosomal instability in
detail. In this study, we have chosen to focus on superficial EAC
because of the essential importance of prognostic information for
optimizing therapy. In superficial EAC, we find that extreme low
or high CNA burden connotes a relatively favorable prognosis in
comparison to intermediate levels. Although we focus on
superficial EAC, our results are likely to be generalizable because
we saw significant similarities between superficial EAC and
published results from unselected EAC with respect to patterns
of recurrent gains and losses.
In our analysis of CNAs by high density SNP array, we see a 40-
fold variation in the total number of CNAs detected in the tumor
genome of superficial EAC. This suggests that there are significant
differences between individual tumors in pathways that regulate
Figure 4. Overall Survival and Time to First Recurrence for
Superficial EAC Stratified by Total CNA Count. (A) Patients with
intermediate total CNA counts had significantly worse overall survival
than patients with low or high total CNA counts (log rank p-
value = 0.032). (B) Similarly, patients with intermediate total CNA counts
had significantly shorter time to first recurrence than those with low or
high total CNA counts (log rank p-value= 0.010).
doi:10.1371/journal.pone.0079079.g004
Table 3. Total CNA Count in Relation to Potential Pathologic
Prognostic Variables.
Total CNA Count
Low Intermediate High
T stage* T1a 2 (20%) 3 (14.3%) 1 (10%)
T1b-T2 8 (80%) 18 (85.7%) 9 (90%)
N stage* N0 8 (80%) 12 (57.1%) 6 (60%)
N1+ 2 (20%) 9 (42.9%) 4 (40%)
M stage* M0 10 (100%) 20 (95.2%) 10 (100%)
M1 0 (0%) 1 (4.8%) 0 (0%)
Grade* WD-MD 6 (60%) 12 (57.1%) 7 (70%)
PD 4 (40%) 9 (42.9%) 3 (30%)
Angioinvasion* no 8 (80%) 12 (57.1%) 7 (70%)
yes 2 (20%) 9 (42.9%) 3 (30%)
T size (cm),
mean{
2.26 3.30 3.03
No. LN resected,
mean{
23 24 21
*For categorical variables, none of the differences between groups was
statistically significant when comparing across the three groups nor in pairwise
comparisons with low CNA count (p-value.0.05, Fisher’s exact test).
{The difference in tumor size and mean number of resected lymph nodes was
not significant across the three CNA count groups (p-value.0.05, Kruskal-Wallis
one way ANOVA), nor in pairwise comparisons (p-value.0.05, Mann-Whitney U
Test).
doi:10.1371/journal.pone.0079079.t003
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chromosomal replication, segregation and repair of DNA damage.
Chromosomal instability is a reflection of the inability of tumor
cells to maintain a stable genome and is measured by directly
evaluating intratumoral heterogeneity or chromosomal changes in
tumor cell populations over time [49]. SNP arrays capture a static,
aggregate image of a population of tumor cells, but give a more
detailed portrait of arm level CNAs and segmental CNAs present
in the genome. Nevertheless, the total CNA count by SNP array
has been shown to correlate with direct measures of chromosomal
instability and tumor ploidy in colorectal cancer cell lines [25]. In
our analysis of segmental variation in copy number, we did not
evaluate tumor ploidy, per se. Tumor ploidy might alter the
estimated magnitude of copy number changes relative to matched
normal cells, but this would not affect the total number of
segmental CNAs. However, polyploidy would be expected to
reduce the detection of single copy changes [48]. We evaluated
chromosome 8 and chromosome 7 copy number by FISH using
centromeric probes and found no evidence of higher centromere
counts per nucleus among tumors with low CNA counts. If
anything, increased ploidy appeared to be more common among
tumors with high CNA counts—suggesting that we may be
underestimating the magnitude of difference between tumors with
low CNA counts and those with high counts. The actual CNA
counts and CNA size estimates observed will also vary based on
segmentation parameters, but relative differences in CNA should
persist.
Chromosomal instability and aneuploidy are most often
associated with poor prognosis in cancer, a generalization that is
true for multiple cancer types [49]. However, there is evidence
suggesting a more complex relationship between genomic
instability and clinical behavior. One recent study using the
CIN70 index [50] to measure chromosomal instability, found a
paradoxical relationship between CIN70 scores and survival in
estrogen receptor negative breast cancer, ovarian cancer, squa-
mous carcinoma of the lung and gastric adenocarcinoma [30].
Tumors with the highest quartile CIN70 score had significantly
better prognosis than tumors in all three other quartiles. Tumors
in the third quartile had the worst prognosis. Our findings are
similar, in that superficial EAC with high total CNA counts had
favorable prognosis compared to those in the middle quartiles
which had significantly worse survival outcome. Another study of
serous ovarian carcinomas computed a total aberration index
(TAI) from copy number profiles obtained from array CGH or
SNP array platforms [31]. The TAI represents a weighted average
copy number across the entire genome. Patients with TAI above
the median had significantly better overall and progression free
survival than those with TAI below the median. They did not
report quartiles. The prognostic significance of TAI was also
shown to be independent of age, tumor grade and tumor stage in
their multivariate analysis.
Variation in the degree of aneuploidy not only has prognostic
significance, but it has potential therapeutic implications. On one
hand, chromosomal instability has been shown to facilitate the
acquisition of drug resistance in tumor cells [25]. On the other
hand, experimentally induced chromosomal instability has been
shown to sensitize tumor cells to taxol, an anti-mitotic drug that
inhibits microtubule formation [51]. Tumors with BRCA1
deficiency that compromises homologous recombination of DNA
double-strand breaks have high levels of genomic instability and
are sensitive to poly-ADP ribose polymerase (PARP) inhibitors and
DNA cross-linking compounds [52]. Evaluation of genomic
instability may identify EAC that are sensitive to agents that
exploit deficiencies in DNA repair or maintenance of structural
and numerical chromosomal integrity. Given the small number of
patients with available data on post-operative chemoradiotherapy
(23 of 41), we were unable to explore this question in our study.
Our analysis of CNAs in superficial EAC confirmed many gains
and losses targeting receptor tyrosine kinases, cell cycle regulatory
proteins, and lineage specifying transcription factors. Although
superficial EAC is primarily treated by surgical resection, selective
inhibitors that target HER2, EGFR, MET and KRAS—one or
more of which we found to be amplified in approximately 40% of
superficial EAC—are plausible therapeutic targets for recurrent
superficial EAC. Amplification of FGFR2 has been reported to
occur in 5–10% of gastric and esophageal adenocarcinomas by
SNP array analysis [14,19], but we did not see evidence of copy
number gain in our cohort. Nor did we see copy number gains
involving MDM2, EPHB6, MYB, MCL1 or PRKCi, nor losses in
PARK2, CASP3, ATM and RB1. We did see recurrent CNAs at
genomic fragile sites (FHIT, WWOX, MACROD2 and DMD) as
previously described [47]. WWOX and FHIT are tumor
suppressor genes that are mutated in a wide range of cancers
and could result in greater genomic instability given their roles in
detecting genotoxic stress and regulation of the cellular response to
genomic damage [45,46]. Although deletion events affecting
WWOX and FHIT were marginally more common in tumors
with intermediate or high CNA counts (compared to low), the
differences were not statistically significant across all three groups.
Hence, we cannot suggest a causal role for these fragile site
deletions in the overall level of segmental aneuploidy. The study
was not sufficiently powered to evaluate the prognostic significance
of copy gain or loss of individual genes due to the low prevalence
of most of the CNAs targeting biologically significant genes.
On a qualitative level, amplification events involving HER2 and
EGFR were characteristically high copy number with variation in
copy number throughout the amplified segment (as depicted in
Figure 3). We cannot exclude differences in attenuation curves of
neighboring SNP probes as an explanation for this phenomenon
[53], but other mechanisms could account for this, such as
successive somatic DNA alterations or chromothripsis [54],
Chromothripsis is estimated to occur in approximately 2% of
cancers, including esophageal carcinoma [55]. It is characterized
by multiple genomic alterations involving random, but clustered
copy number changes of similar size and alternating copy number
profile, often resulting in loss deletion of genomic material. The
copy gains in EGFR and HER2 did not fit this typical profile. A
survey of our data did not locate regions of likely chromothripsis.
However, other methods (e.g. paired end sequencing) are better
suited to identify the characteristic sequence inversions and
rearrangements of segment order that occur as a result of
chromothripsis [54].
Other regions of recurrent CNA merit further investigation due
to the potential role in the pathogenesis of EAC. For example, the
region of chromosome 12q24.13 spanning the PTPN11 gene was
amplified in approximately 17% of cases (Table S1). PTPN11
encodes the protein tyrosine phosphatase Shp2. It is an intriguing
candidate because PTPN11 is mutated in Noonan and LEOP-
ARD syndromes and activating mutations have been implicated in
the pathogenesis of leukemia while inactivating mutation promotes
the development of hepatocellular carcinoma [56].
Our study has limitations, including the retrospective design, the
relatively small size of the study cohort compared to the largest
studies and our use of FFPE tissue. As a retrospective study,
patients did not receive rigorously standardized treatment and
follow-up. We attempted to control for potential confounding
variables in our analysis of clinical outcome, but we were unable to
control for the effects of post-operative chemoradiation treatment.
Although the number of cases in our study did not allow us to
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evaluate the prognostic significance of individual CNAs, ours is a
large cohort of superficially invasive EAC and we believe that our
data make a positive contribution to the characterization of the
prevalence of CNAs and the potential clinical significance of
segmental aneuploidy in a generally understudied disease. Lastly,
to study the superficially invasive subset of EAC, we required
FFPE specimens in the clinical archive. There is an inherent
reduction in data quality associated with the use of FFPE
specimens in comparison to high quality frozen samples.
Nevertheless, FFPE tissue represents a much larger repository of
clinically annotated samples. Based on prior reports, reliable copy
number data can be obtained from FFPE samples using a variety
of SNP array platforms, in spite of reduced data quality [32].
Supporting the validity of our data is the fact that we identified a
large majority of recurrent copy gains and losses that have been
previously identified in esophageal and gastric cancer. The
prevalence of these CNAs in our samples was similar to what
has been reported. The reduction in data quality due to formalin
fixation would be expected to influence detection of CNAs, but we
saw no correlation between standard data quality metrics and the
number of CNAs to suggest that this was a major factor in total
CNA count variation. Still, validation of the results in cohorts of
more advanced EAC as well and evaluation of segmental
aneuploidy and chromosomal instability as a marker of response
to chemotherapy or radiation therapy will be of interest.
Our study highlights the potential clinical utility of genome wide
analysis of copy number changes. First, it allows for the
simultaneous evaluation of multiple potential therapeutic targets
that are defined by copy gain or loss. This will become increasingly
relevant as clinical trials evaluate the efficacy of targeted
therapeutic agents in addition to trastuzumab for the treatment
of HER2 amplified gastroesophageal adenocarcinomas [37]. Of
course, SNP array technology may not ultimately prove to be the
ideal platform because of the inability to interrogate mutations
that occur at a smaller scale (i.e. at the sequence level). Second, the
quantitative assessment of CNAs can be used to determine the
pattern (whole chromosome versus segmental) and the extent of
aneuploidy. Aneuploidy and genomic instability are promising
prognostic markers. Future studies should address whether the
degree of aneuploidy or genomic instability can predict response to
therapies that target cells based on their capacity to respond to
DNA damage. Prognostic and predictive biomarkers are needed
for superficial EAC in order to optimize therapeutic outcomes for
this potentially curable form of cancer.
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